Cizutamig

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCizutamig
Drug Alias NameEMB-06CND-106CN106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-BCMAAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsFood HypersensitivityHypersensitivity, ImmediatePemphigus +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Epimab Biotherapeutics, Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Tanti Biomedical Technology Co LtdCandid Therapeutics IncVignette Bio Inc +[5] 
Inactive CompaniesN/A
Active IndicationsFood HypersensitivityHypersensitivity, ImmediatePemphigus +[8] 
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A